Latest News

VIDEO: PCSK9 inhibitors show benefit in high-risk groups

PHILADELPHIA — In this video exclusive, Pam R. Taub, MD, FACC, cardiologist and associate professor of medicine at University of California, San Diego, highlights the benefits of PCSK9 inhibitors in high-risk patients.
Taub discusses recent data that have demonstrated benefit of PCSK9 inhibitors for reducing major adverse CV events and in subgroups of high-risk patients such as those with multivessel disease, peripheral artery disease, type 2 diabetes and elevated lipoprotein A.
Watch the video for more.

Source link




Related posts

How memories form and fade

Newsemia

Scientists edge closer to root causes of multiple sclerosis

Newsemia

Cutting-edge procedure mends Jagger's 'heart of stone'

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy